Duloxetine in the treatment of major depressive disorder: Comparisons of safety and efficacy

Journal of the National Medical Association

Volumn 98, Issue 3, 2006, Pages 437-447

  Bailey, Rahn K ^a   Mallinckrodt, Craig H ^b   Wohlreich, Madelaine M ^b   Watkin, John G ^b   Plewes, John M ^b  

^a National Medical Association   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; Depression; Duloxetine

Indexed keywords

DULOXETINE;

ADULT; AFRICAN AMERICAN; ANOREXIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAPHORESIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN AMERICAN; FEMALE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MALE; NAUSEA; PAIN; PATIENT GLOBAL IMPRESSION OF IMPROVEMENT SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; VISUAL ANALOG SCALE; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; THIOPHENES; TREATMENT OUTCOME;

EID: 33644801014     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. U.S. Census Bureau. The Black Population: 2000. Washington, DC: U.S. Government Printing Office.
2. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 1999. 2003. U.S. Department of Health and Human Services.
3. Robins L, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991.
4. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994;151:979-986.
5. Jackson-Triche ME, Greer SJ, Wells KB, et al. Depression and health-related quality of life in ethnic minorities seeking care in general medical settings. J Affecf Disord. 2000;58:89-97.
6. U.S. Department of Health and Human Services. Mental Health: Culture, Race, and Ethnicity-A Supplement to Mental Health: a Report of the Surgeon General. Rockville, MD: Center for Mental Health Services; 2001.
7. Young AS, Klap R, Sherbourne CD, et al. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry. 2001;58:55-61.
8. Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States: prevalence and conformance with evidence-based recommendations. J Gen Intern Med. 2000;15:284-292.
9. Melti CA, Croghan TW, Hanna MP, et al. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry. 2000;61:16-21.
10. Sirey JA, Meyers BS, Bruce ML, et al. Predictors of antidepressant prescription and early use among depressed outpatients. Am J Psychiatry. 1999;156:690-696.
11. Sclar D, Robison L, Skaer T, et al. Antidepressant prescribing patterns: a comparison of blacks and whites in a Medicaid population. Clin Drug Invest. 1998;16:35-140.
12. Blazer DG, Hybels CF, Simonsick EM, et al. Marked differences in antidepressant use by race in an elderly community sample: 1986-1996. Am J Psychiatry. 2000;157:1089-1094.
13. Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry. 2001;62(Suppl 13):13-19.
14. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76-89.
15. Bradford LD, Gaedigk A, Leeder JS. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull. 1998;34:797-804.
16. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991;50:308-313.
17. Ziegler VE, Biggs JT. Tricyclic plasma levels. Effect of age, race, sex, and smoking. JAMA. 1977;238:2167-2169.
18. Silver B, Poland RE, Lin K. Ethnicity and the pharmacology of tricyclic antidepressants. In: Lin KM, Poland RE, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC: American Psychiatric Press; 1993.
19. Raskin A, Crook TH. Antidepressants in black and white inpatients. Differential response to a controlled trial of chlorpromazine and imipramine. Arch Gen Psychiatry. 1975;32:643-649.
20. Overall JE, Hollister LE, Kimbell I Jr, et al. Extrinsic factors influencing responses to psychotherapeutic drugs. Arch Gen Psychiatry. 1969;21:89-94.
21. Brown C, Schulberg HC, Sacco D, et al. Effectiveness of treatments for major depression in primary medical care practice: a post hoc analysis of outcomes for African American and white patients. J Affect Disord. 1999;53:185-192.
22. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv. 1998;49:239-240.
23. Rollman BL, Hanusa BH, Belnap BH, et al. Race, quality of depression care, and recovery from major depression in a primary care setting. Gen Hosp Psychiatry. 2002;24:381-390.
24. Fabrega H Jr, Mulsant BM, Rifai AH, et al. Ethnicity and psychopathology in an aging hospital-based population. A comparison of African-American and Anglo-European patients. J Nerv Ment Dis. 1994;182:136-144.
25. Livingston RL, Zucker DK, Isenberg K, et al. Tricyclic antidepressants and delirium. J Clin Psychiatry. 1983;44:173-176.
26. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002;36:106-132.
27. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63:225-231.
28. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389-399.
29. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308-315.
30. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383-390.
31. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005;39:43-53.
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: APA; 1994.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
34. Guy W. ECDEU assessment manual for psychopharmacology, revised 1976. Rockville, MD: National Institutes of Mental Health; 1976.
35. DeLoach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998;86:102-106.
36. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy. 1992;22:307-319.
37. Iwata N, Turner RJ, Lloyd DA. Race/ethnicity and depressive symptoms in community-dwelling young adults: a differential item functioning analysis. Psychiatry Res. 2002;110:281-289.
38. Brown C, Schulberg HC, Madonia MJ. Clinical presentations of major depression by African Americans and whites in primary medical care practice. J Affect Disord. 1996;181-191.
39. Riley JL III, Wade JB, Myers CD, et al. Racial/ethnic differences in the experience of chronic pain. Pain. 2002;100:291-298.
40. O'Sullivan MJ, Peterson PD, Cox GB, et al. Ethnic populations: community mental health services ten years later. Am J Community Psychol. 1989;17:17-30.
41. Sue S, Fujino DC, Hu LT, et al. Community mental health services for ethnic minority groups: a test of the cultural responsiveness hypothesis. J Consult Clin Psychol. 1991;59:533-540.
42. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003;64:1237-1244.